Compare Pfizer Inc (PFE) vs Synchrony Financial (SYF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Synchrony Financial — how do they compare? Pfizer Inc trades at $27.74 (market cap $159.59B), while Synchrony Financial trades at $73.83 (market cap $23.40B). The key difference: Pfizer Inc is far larger — about 6.8× Synchrony Financial's market cap, and Pfizer Inc pays the higher dividend (6.14%). Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and Synchrony Financial for 28 Days on average.
| PFE | SYF | |
|---|---|---|
Market Cap | $159.59B | $23.40B |
Volume | 30,937,010 | 2,108,179 |
Sector | Health | Financials |
52-Week High | $29.02 | $88.47 |
52-Week Low | $23.67 | $63.78 |
Typical Hold Time | 158 Days | 28 Days |
Enterprise Value | $211.09B | $23.64B |
Dividend Yield | 6.14% | 1.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
SYF trades at $71.93, down 0.32% on the day, with a bearish technical signal from moving averages. The stock is valued attractively with a P/E of 7.38 and P/S of 1.68, supported by strong profitability including a 23.4% net income margin and 22.23% ROE. Recent earnings have consistently beaten estimates, and the company is expanding through partnerships like the Vetspire tie-up and OpenAI collaboration to enhance its digital payment solutions.
The outlook remains positive given the low valuation, high profitability, and strategic growth initiatives. Key risks include potential credit quality deterioration amid economic uncertainty and heavy investing cash outflows. Analyst consensus is bullish with a $88.18 price target, suggesting significant upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Synchrony Financial
Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.
Read more on SYF →
